ZINBRYTA® (daclizumab) voluntarily withdrawn from markets worldwide

JOIN

ZINBRYTA^® (daclizumab) voluntarily withdrawn from markets worldwide

https://www.brainwork.md/content/uploads/2018/03/Brainwork-MS.jpg 1600 1067 Julien Ferrari, PharmD, PhD Julien Ferrari, PharmD, PhD https://secure.gravatar.com/avatar/3b67ea7b895dced9b9ed9795a9851ab4?s=96&d=mm&r=g 6th March 2018 13th July 2018

Biogen and AbbVie announced on 6 March 2018 a voluntary worldwide withdrawal of ZINBRYTA^® (daclizumab) for relapsing MS, following reports of inflammatory encephalitis and meningoencephalitis among European patients.

You can find the original press release here.